Q2 2026 results

Significant growth with important pipeline progress

Conference call and webcast for analysts and investors

16 July 2026

Forward-looking statements

In order to utilise the 'Safe Harbor' provisions of the United States Private Securities Litigation Reform Act of 1995, Swedish Orphan Biovitrum AB (publ) is providing the following cautionary statement. This presentation contains forward-looking statements with respect to the financial condition, results of operations and businesses of Swedish Orphan Biovitrum AB (publ), By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, the loss or expiration of patents, marketing exclusivity or trade marks; exchange rate fluctuations; the risk that R&D will not yield new products that achieve commercial success; the impact of competition, price controls and price reductions; taxation risks; the risk of substantial product liability claims; the impact of any failure by third parties to supply materials or services; the risk of delay to new product launches; the difficulties of obtaining and maintaining governmental approvals for products; the risk of failure to observe ongoing regulatory oversight; the risk that new products do not perform as we expect; and the risk of environmental liabilities.

Agenda

Business Update - Guido Oelkers

Chief Executive Officer

R&D Pipeline - Lydia Abad-Franch

Head of R&D and Medical Affairs, Chief Medical Officer

Financials - Henrik Stenqvist

Chief Financial Officer

Summary and Q&A

Key takeaways for Q2 2026

- **Significant Q2 performance**: **+29%** growth at CER and **35%** adj. EBITA margin
- **Aspaveli C3G / IC-MPGN continued early launch momentum**
- **Pozdeutinurad demonstrating meaningful urate reduction in REDUCE 2**
- **NASP: CRL received on manufacturing with a clear path to resubmission**
- **Gamifant: EMBRACE II in IDS pivotal study to initiate in H2**
- **Strong business performance resulting in increased full year Outlook**

Per cent growth calculated in CER

Strong growth of 29% at CER in Q2 delivered by our portfolio and across all regions

Total net sales, SEK M, growth at CER



+53%

Strategic portfolio, SEK M



Revenue by region



Revenue at actual exchange rates; change at constant exchange rates (by segment and geographic area). International region previously called rest of the world. Other refers to royalty and the majority of royalties received are attributable to North America.
1. Strategic portfolio includes Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant, Vonjo, Zynlonta and Tryngolza and royalties from Altuviiio and Beyfortus.

Strong launch cadence and milestone achievement continues building a highly differentiated portfolio



Status Q2/26

- Strong launch momentum
- HLH/MAS in EU & Japan filing ongoing
- Europe launch ongoing
- sHTG in EU filing ongoing, FCS launch underway
- **FDA CRL: approval delay, resubmission planned**
- **REDUCE 2 positive topline data**
- FREEDOM interim data at ISTH
- PAXIS interim analysis passed
- **EMBRACE II to initiate in H2**

1. Phase 4 Synovitis trial (SHINE) ongoing, it is not currently expected that a label change for Altuvoct is pursued, but positive trial results is a significant development for haemophilia A patients and significant data generation activity to differentiate Altuvoct
2. Phase 2 VEXAS trial (PAXIS) ongoing, timeline for further development / potential new indication launch is dependent upon Ph2 results and regulator feedback
3. Phase 2a IDS trial (EMBRACE) topline results announced Jan 2026, timeline for further development / potential new indication launch is dependent upon regulator feedback

Altuvoct: Continued expansion in Haemophilia A prophylaxis in our territory

ALTUVOCT
efanesoctocog alfa (recombinant coagulation factor VIII, Fc-Von Willebrand Factor-XTEN Fusion Protein)

Haemophilia A sales
SEK 2,256 M
+41% Q2



Altuvoct: Best in class product

- Continued strong momentum of Altuvoct
  - Growth at CER: +149% YoY, +20% QoQ
- Launched in 30 countries, including key European markets

Altuvoct launch in three waves:

- **Wave 1:** 6 countries incl. DACH – significant portion of the market potential captured
- **Wave 2:** Active rollout continues; France launched in Q4 2025 and Italy in January 2026 – material headroom for future growth
- **Wave 3:** Remaining European & international markets – launches pending

Sales in SEK M at actual exchange rates; change at constant exchange rates

Aspaveli: Launch progressing across markets, backed by new long-term and RWE data in C3G and IC-MPGN



Sustained launch momentum and expanding evidence base

- Continued expansion of **Nephrology launch**, and PNH remaining stable. UK approval in Q2; National reimbursement available in Germany, Spain and Austria
- **enFuse on-body delivery device launched**, with the first patients dosed and very positive early feedback
- **Additional VALIANT / VALE data** presented at ERA
  - 52-week eGFR results: sustained stabilisation of kidney function
  - RWE of pegcetacoplan in C3G and IC-MPGN: extending the profile beyond the controlled trial setting

On track to achieve 2026 target of 400–500 Aspaveli patients in nephrology

Sales in SEK M at actual exchange rates; change at constant exchange rates, C3G and IC-MPGN: Complement 3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis
RWE: Real world evidence
UK uptake remains contingent on a positive NICE recommendation, which is pending

Doptelet: Continues to deliver strong momentum globally

Doptelet
SEK 1,628 M
+36% Q2



Doptelet still accelerating as a high-growth global franchise

- **Doptelet's differentiated profile** – strong efficacy with fewer dietary restrictions – combined with excellent execution has established it as **a leading choice in ITP**
- The brand has evolved into a **truly global franchise**, with strong momentum and sustained growth across all three major regions
- Expanding international launches across **Japan, South Korea**, **Taiwan, LATAM**, the **Middle East**, and **Eastern Europe** are expected to significantly increase ex-US contribution over time
- Strong uptake in Japan's ITP launch further reinforces Doptelet's **global growth potential**

ITP: Idiopathic Thrombocytopenic Purpura
Sales in SEK M at actual exchange rates; change at constant exchange rates

Gamifant HLH/MAS: US launch driving growth with strong momentum

Gamifant
SEK 794 M
+29% Q2



gamifant® emapalumab-lzsg

HLH/MAS launch

- First-ever treatment for adults and children with Macrophage Activation Syndrome (MAS) in Still's disease
- Strong **new patient demand** continues to drive growth
- Growth supported by International markets following FDA label
- **EU and Japan filing completed for HLH/MAS**
  - Japan decision expected 2026, EU 2027

Sales in SEK M at actual exchange rates; change at constant exchange rates
HLH/MAS: Haemophagocytic lymphohistiocytosis / macrophage activation syndrome

Gamifant IDS: Fastest path to patients discussed with EMA's Emergency Task Force

Fast-to-market approach

- Aligning with EMA feedback
- Advancing **with registrational Phase 2b/3 study in Europe**

EMBRACE-II

Phase 2b/3 randomised study – up to 1,800 patients planned

Registration-enabling study design[1]



EMA: European Medicines Agency

1: Co-Sponsorship with The Hellenic Institute for the Study of Sepsis (HISS)

Establishing Sobi as a leader in gout



NASP

- CRL: June 2026 relating to manufacturing
- No clinical safety or efficacy concerns were identified that impact approvability
- Resubmission planned in 6-12 months
- Some launch cost shift to 2027

Pozdeutinurad

- REDUCE 2 positive topline data in Q1 demonstrating significant urate lowering and a favorable efficacy and tolerability profile
- REDUCE 1 on track for readout in H2 2026
- Filing in US 2027

Launches subject to regulatory approval. NASP, nanoencapsulated sirolimus plus pegadricase. 1: Of the estimated 9-12 million patients according to underlying prevalence (Chen-Xu et al., Arthritis Rheumatol 2019 (NHANES); Yokose et al., JAMA Netw Open 2023); 2: Patients either on 2L treatment options (e.g., Febuxostat, Probenecid) or who remain symptomatic under Allopurinol (e.g., presence of tophi, flares) or not reaching target of <6mg/dl; 3: Core addressable uncontrolled gout population 10-20k patients, based on Sobi market research using claims data and expert input.

Guidance upgrade: Strong HY performance across the portfolio leading us to raise full-year guidance

Strong business performance in the first half of the year

Outstanding HY growth of 26% in CER

Strong margin evolution, 37% adjusted EBITA

Significant pipeline progress

6 major ongoing or upcoming launches: Aspaveli launched in Nephrology in Q1

Filed Tryngolza in sHTG and preparing for launch in 2027

Arthrosi integrated and positive pozdeutinurad REDUCE 2 data

Revised Full Year 2026 outlook

Sales growth

and

Adjusted EBITDA



Q2 R&D Update

Lydia Abad-Franch
Head of R&D and Chief Medical Officer

Continued pipeline progress in Q2 2026

Pozdeutinurad	**Progressive gout** Positive topline data of REDUCE 2 (pivotal Phase 3)
NASP	**Uncontrolled gout** FDA Complete response letter – resubmission planned
Zynlonta	**2L in relapsed or refractory DLBCL** LOTIS-5 combination study topline results
Tryngolza	**Severe hypertriglyceridemia (sHTG)** Pooled analysis of patients with TG ≥880mg/dl at EAS
Aspaveli	**C3G & primary IC-MPGN** enFuse device certified for home use by lay persons
Kineret	**Still's disease (sJIA and AOSD)** Approved in Japan
Vonjo	**Myelofibrosis** PACIFICA Phase 3 confirmatory study fully enrolled

C3G and IC-MPGN: Complement 3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis. **DLBCL:** Diffuse large B-cell lymphoma. **TG:** Triglycerides. **EAS:** European Atherosclerosis Society. **sJIA:** systemic Juvenile Idiopathic Arthritis. **AOSD:** Adult-Onset Still's Disease

Advancing our gout franchise

Pozdeutinurad: A rationally engineered highly selective new treatment approach



- Next generation URAT1 inhibitor, once-daily oral

REDUCE 2 positive topline data

- Both doses met the primary endpoint: serum uric acid (sUA) <6 mg/dL at month 6
  - **75 mg: 69.2%** vs 8.1%; p<0.0001
  - **50 mg: 56.6%** vs 8.1%; p<0.0001
  - Overall **well tolerated**, and the safety profile was consistent with previous studies
- **REDUCE 2 data expected to be presented at scientific conference in Q4**

REDUCE 1 topline readout in Q4

NASP: Potential monthly two-component uricase therapy

FDA CRL received: manufacturing-driven regulatory delay, not a clinical or strategic setback

- NASP remains approvable, with a clear path to resubmission
- No new safety or efficacy concerns affecting approvability
- Manufacturing controls and facilities are addressable
- Clear, actionable path forward
  - Remediation plan is active
  - FDA engagement continues
- **Long-term opportunity remains intact**

Progressive gout >200k patients[1] | **Uncontrolled gout 15k patients[2]**

NASP, nanoencapsulated sirolimus plus pegadricase.
1: Patients either on 2L treatment options (e.g., Febuxostat, Probenecid) or who remain symptomatic under Allopurinol (e.g., presence of tophi, flares) or not reaching target of <6mg/dl;
2: Core addressable uncontrolled gout population 10-20k patients, based on Sobi market research using claims data and expert input.

Olezarsen 80 mg reduced acute pancreatitis by 85% and triglycerides by 66% in sHTG ≥ 880 mg/dL

New CORE/CORE2 subgroup analysis presented at European Atherosclerosis Society (EAS) Congress 2026

Primary endpoint: TG reduction at 6 months



Acute Pancreatitis



Results support efficacy and safety of olezarsen in patients with severe hypertriglyceridemia, TG ≥ 880 mg/dL (10 mmol/L), without offsetting safety concerns

TG: Triglycerides

Zimerman A. et al. 2026 EAS oral presentation

Progress to be continued in 2026-27

Anticipated pipeline news flow

2026 H2

- **Aspaveli** – C3G & primary IC-MPGN
  - Japan regulatory decision
- **Gamifant** – HLH / MAS in Still's disease
  - Japan regulatory decision
- **Pozdeutinurad** – Progressive gout
  - REDUCE 1 (AR882-301) data readout
- **Tryngolza** – sHTG ≥880 mg/dL
  - EU CHMP opinion

2027

- **Pozdeutinurad** – Progressive gout
  - FDA submission
- **NASP** – Uncontrolled gout
  - FDA resubmission
- **Gamifant** – HLH / MAS in Still's disease
  - EU regulatory decision
- **Vonjo** – Myelofibrosis
  - PACIFICA Phase 3 readout
- **Vonjo** – VEXAS
  - PAXIS Phase 3 readout

C3G and pIC-MPGN: Complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. HLH/MAS: Haemophagocytic lymphohistiocytosis / macrophage activation syndrome. IDS: Interferon gamma driven sepsis. NASP: Nanoencapsulated sirolimus plus pegadricase (formerly known as SEL-212). VEXAS: Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome

Q2 Financials

Henrik Stenqvist
Chief Financial Officer

Q2 2026 Revenue and profit & loss

Total revenue (SEK M)



Absolute amounts in SEK million (except EPS) and at actual exchange rates; change at actual exchange rates (statutory view).

Amounts in SEK M	Q2 2026	Q2 2025	Change	Full-year 2025
Total revenue	**7,842**	6,175	27%	**28,238**
Adjusted Gross profit[1,2]	**6,013**	4,781	26%	**22,270**
Adjusted Gross margin[1,2]	**77%**	77%		**79%**
EBITA[1]	**2,843**	1,863	53%	**10,817**
Adjusted EBITA[1,2]	**2,746**	2,100	31%	**11,341**
EBITA margin[1]	**36%**	30%		**38%**
Adjusted EBITA margin[1,2]	**35%**	34%		**40%**
Profit for the period	**1,098**	634	73%	**476**
EPS, before dilution, SEK	**3.17**	1.85	71%	**1.39**
Adjusted EPS, before dilution, SEK[1,2]	**4.00**	2.38	68%	**16.95**
Operating cash flow	**1,912**	1,448	32%	**8,565**
Net debt[1]	**16,126**	11,386		**10,081**

1. Alternative Performance Measures (APM); see the report for further information
2. Items affecting comparability (IAC); see the report for further information

Sobi Outlook 2026 - Updated

Key drivers for 2026 outlook - H1 update

- Progress with commercial portfolio and continued Altuvoct launch
  - **H1 Growth 26% at CER**
- Critical investments in 2026 for future revenue growth:
  - **Adj EBITA margin 37% for H1**
  - **Some NASP launch cost moved to 2027**
  - **Gamifant IDS Phase 2b/3 startup**
- Balanced by re-allocation of resources towards new investments and rigorous cost control

2026 Updated Outlook

Revenue

Anticipated to grow by a mid-to high-teens percentage at CER
(previously low double-digit)

Adjusted EBITA margin

Anticipated to be in the mid-to high-30s percentage of revenue
(previously mid 30s)

NASP: nanoencapsulated sirolimus plus pegadricase, IDS: interferon-gamma-driven sepsis

Summary and Q&A

Guido Oelkers

Chief Executive Officer

We continue to make progress towards our 2030 ambition of doubling Sobi to 55bn SEK[1]

Revenue, *in SEK B*

ILLUSTRATIVE ONLY, NOT TO SCALE



1 Revenue risk corridor of +/- 10% by 2030


Q&A

Current Development Pipeline

Major ongoing clinical studies and medicines in registration in a major region or country



NASP: nanoencapsulated sirolimus plus pegadricase
CAR-T: chimeric antigen receptor T-cell
C3G & primary IC-MPGN: complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis
HLH/MAS: Haemophagocytic lymphohistiocytosis / macrophage activation syndrome
1. Proof of concept research collaboration

Sustainability drives our strategic business priorities and decisions – progress Q2 2026

Patient commitment

- Access to treatment
- Patient centricity and engagement
- Patient and product safety
- Responsible marketing & sales
- Ethical R&D, focused on medical need

Responsible behaviour

- Safe and healthy work
- A fair and inclusive workplace
- Lower environmental footprint
- Less resource consumption
- Responsible sourcing
- Compliance and anti-corruption

Main achievements Q2 2026

- Member of the 2026 Dow Jones Best in Class (DJ BIC) Index World & Europe
- Included on list of World's Most Impactful Companies 2026 by TIME and Statista
- Maintained no. 2 position for patient engagement in the Corporate Reputation of Pharma Report 2025/2026
- Initiative Unite4Rare winner in the 2026 PFMD Made with Patients Awards

Thank you

Swedish Orphan Biovitrum AB (publ)
SE-112 76 Stockholm • Sweden
www.sobi.com